Johns Hopkins HIV Guide
Sofosbuvir + velpatasvir
INDICATIONS
FDA
FDA
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Acute HCV infection
- Current AASLD/IDSA guidance recommends treating acute viremic HCV without waiting for spontaneous clearance, using the same regimens as chronic HCV; abbreviated SOF/VEL courses are not recommended.[9]
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 7, 2026
Citation
Tsai, Y. V, and Janessa M Smith. "Sofosbuvir + Velpatasvir." Johns Hopkins HIV Guide Johns Hopkins HIV Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, hopkinsguides.org/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir.
Tsai YV, Smith JM. Sofosbuvir + velpatasvir. Johns Hopkins HIV Guide Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. https://hopkinsguides.org/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir. Accessed October 13, 2026.
Tsai, Y. V., & Smith, J. M. (2026). Sofosbuvir + velpatasvir. In Johns Hopkins HIV Guide Johns Hopkins HIV Guide. The Johns Hopkins University. https://hopkinsguides.org/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir
Tsai YV, Smith JM. Sofosbuvir + Velpatasvir [Internet]. In: Johns Hopkins HIV Guide Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. [cited 2026 October 13]. Available from: https://hopkinsguides.org/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sofosbuvir + velpatasvir
ID - 545302
A1 - Tsai,Y.,Pharm.D.
AU - Smith,Janessa,PharmD, BCPS
Y1 - 2026/10/07/
BT - Johns Hopkins HIV Guide
UR - https://hopkinsguides.org/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
